Human IL3RA (Interleukin-3 receptor) ELISA Kit
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human IL3RA (Interleukin-3 receptor) ELISA Kit
category
ELISA Kits
provider
FineTest
reference
EH2459
tested applications
ELISA
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | ELISA Kits |
| Reactivity | Human |
| Detection Method | Colorimetric |
| Assay Data | 4 hours |
| Assay Type | Sandwich ELISA, Double Antibody |
| Test Range | 31.25-2000pg/ml |
| Sensitivity | 18.75pg/ml |
| Size 1 | 96T |
| Tested Applications | ELISA |
| Sample Type | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Availability | Shipped within 10-14 working days. |
| Storage | 2-8 °C for 12 months |
| UniProt ID | P26951 |
| Alias | IL-3 receptor subunit alpha,IL3R,CD123,IL3RX,IL3RY,IL3RAY,hIL-3Ra,IL-3R-alpha, |
| Background | Elisa kits for IL3RA |
| Status | RUO |
IL3RA, also known as CD123, encodes the alpha subunit of the interleukin-3 (IL-3) receptor, an essential receptor in hematopoiesis and immune cell regulation. IL3RA pairs with the common beta subunit (CSF2RB or IL3RB) to form the functional receptor complex for IL-3, a cytokine primarily involved in the growth, differentiation, and survival of various blood cell lineages. The IL-3 receptor is primarily expressed on hematopoietic progenitor cells and is particularly prominent on cells within the myeloid lineage, including basophils, eosinophils, and certain dendritic cells. IL3RA’s role in hematopoiesis is critical as it contributes to regulating immune responses by driving differentiation and survival of blood cell progenitors. The receptor is also crucial in mobilizing immune cells, promoting proliferation and enhancing responses to infection. IL3RA’s clinical significance has grown in recent years, with elevated expression observed in leukemias, particularly in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Its surface expression profile has made IL3RA an important therapeutic target, especially in cancers where IL3RA-positive cells drive disease progression.
